Results 141 to 150 of about 9,749 (194)

Maribavir for the Management of a Complex Cytomegalovirus (CMV) Infection After Liver Transplantation: Refractoriness and Intolerance to Standard Therapies in the Intensive Care Unit. [PDF]

Cureus
Santos L, Inácio H, Cochicho Ramalho A, Rodeia SC, Germano N.   +4 more
europepmc   +1 more source

Outcomes of Dual Kidney Transplantation from Donors with High Pre-Implantation Biopsy Scores.

Am J Nephrol
Comai G, Provenzano M, Gessaroli E, Grandinetti V, Vetrano D, Napoletano A, Abenavoli C, Bini C, Cuna V, Demetri M, Chiappo F, Leone F, Fabbrizio B, Del Gaudio M, Maroni L, Ravaioli M, La Manna G, Corradetti V.   +17 more
europepmc   +1 more source

Efficacy and safety of basiliximab in kidney transplantation

Expert Opinion on Drug Safety, 2005
The efficacy and safety of basiliximab, in combination with different maintenance regimens, are extensively addressed in the available literature. Basiliximab reduces the incidence of acute rejection, allows a safe reduction of steroid dosage, and is ...
Ugo Boggi, Fabio Vistoli, Piero Marchetti   +2 more
exaly   +2 more sources

Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis

Gastroenterology, 2012
Background & AIMS. Basiliximab is a chimeric monoclonal antibody that binds CD25 and thereby inhibits interleukin (IL)-2–mediated proliferation of lymphocytes. IL-2 might contribute to the resistance of T cells to corticosteroids.
Bruce E. Sands, Colin M Dayan, Christopher Sj Probert   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Basiliximab

Drugs, 1999
The chimaeric monoclonal antibody basiliximab specifically binds the alpha subunit of the interleukin-2 (IL-2) receptor on activated T lymphocytes. Through competitive antagonism of IL-2, basiliximab supplements standard immunosuppressive therapy after renal transplantation.
S V, Onrust, L R, Wiseman
  +5 more sources

Basiliximab in pediatric liver transplantation: A pharmacokinetic-derived dosing algorithm [PDF]

Pediatric Transplantation, 2002
The pharmacokinetics and immunodynamics of basiliximab were assessed in 37 pediatric de novo liver allograft recipients to rationally design a dose regimen for this age-group.
Michael Melter, Estella M. Alonso, John M Kovarik   +2 more
exaly   +2 more sources

Removal of Basiliximab by Plasmapheresis

American Journal of Kidney Diseases, 2001
Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis.
C N, Okechukwu, H U, Meier-Kriesche, D, Armstrong, D, Campbell, C, Gerbeau, B, Kaplan   +5 more
openaire   +2 more sources

Basiliximab

Reactions Weekly, 2023
openaire   +2 more sources

Basiliximab

Reactions Weekly, 2021
openaire   +1 more source